Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 11;9(2):182.
doi: 10.3390/biomedicines9020182.

Review on Inflammation Markers in Chronic Kidney Disease

Affiliations
Review

Review on Inflammation Markers in Chronic Kidney Disease

Tadej Petreski et al. Biomedicines. .

Abstract

Chronic kidney disease (CKD) is one of the major health problems of the modern age. It represents an important public health challenge with an ever-lasting rising prevalence, which reached almost 700 million by the year 2017. Therefore, it is very important to identify patients at risk for CKD development and discover risk factors that cause the progression of the disease. Several studies have tackled this conundrum in recent years, novel markers have been identified, and new insights into the pathogenesis of CKD have been gained. This review summarizes the evidence on markers of inflammation and their role in the development and progression of CKD. It will focus primarily on cytokines, chemokines, and cell adhesion molecules. Nevertheless, further large, multicenter studies are needed to establish the role of these markers and confirm possible treatment options in everyday clinical practice.

Keywords: cell adhesion molecules; chemokines; chronic kidney disease; cytokines; inflammation markers.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Groups of inflammation markers that have a role in chronic kidney disease. CKD—Chronic kidney disease; TNF—Tumor necrosis factor; TGF-β—Transforming growth factor beta; CAMs—Cell adhesion molecules; IgSF—Immunoglobulin superfamily.

Similar articles

Cited by

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3:5–14. - PubMed
    1. Webster A.C., Nagler E.V., Morton R.L., Masson P. Chronic Kidney Disease. Lancet. 2017;389:1238–1252. doi: 10.1016/S0140-6736(16)32064-5. - DOI - PubMed
    1. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–733. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed
    1. Mihai S., Codrici E., Popescu I.D., Enciu A.M., Albulescu L., Necula L.G., Mambet C., Anton G., Tanase C. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome. J. Immunol. Res. 2018;2018:2180373. doi: 10.1155/2018/2180373. - DOI - PMC - PubMed
    1. Hojs R., Ekart R., Bevc S., Hojs N. Markers of Inflammation and Oxidative Stress in the Development and Progression of Renal Disease in Diabetic Patients. Nephron. 2016;133:159–162. doi: 10.1159/000447434. - DOI - PubMed

LinkOut - more resources